TY - JOUR
T1 - Effects of placebo and flurazepam on sleep patterns in insomniac subjects
AU - Kales, Joyce
AU - Kales, Anthony
AU - Bixler, Edward O.
AU - Slye, Elaine S.
PY - 1971
Y1 - 1971
N2 - In 12 insomniac subjects placebo had no significant effects on sleep induction, sleep maintenance, or sleep stages, while flurazepam 30 mg. produced clear-cut decreases in sleep latency, wake time after sleep onset, total wake time, and number o f wakes. The decreases were maintained throughout the drug administration period as well as on the first several withdrawal nights, indicating a carry-over effect. There was agreement between the subjective estimates of sleep and the electroencephalogram (EEG) data in terms o f both improvement in sleep induction and sleep maintenance with flurazepam and in the lack o f effects with placebo. Flurazepam produced either no change or a slight decrease in the percentage of rapid eye movement (REM) sleep. There were no increases above base line following withdrawal. Stages 3 and 4 sleep decreased considerably with drug administration, this decrease being maintained during the drug withdrawal period.
AB - In 12 insomniac subjects placebo had no significant effects on sleep induction, sleep maintenance, or sleep stages, while flurazepam 30 mg. produced clear-cut decreases in sleep latency, wake time after sleep onset, total wake time, and number o f wakes. The decreases were maintained throughout the drug administration period as well as on the first several withdrawal nights, indicating a carry-over effect. There was agreement between the subjective estimates of sleep and the electroencephalogram (EEG) data in terms o f both improvement in sleep induction and sleep maintenance with flurazepam and in the lack o f effects with placebo. Flurazepam produced either no change or a slight decrease in the percentage of rapid eye movement (REM) sleep. There were no increases above base line following withdrawal. Stages 3 and 4 sleep decreased considerably with drug administration, this decrease being maintained during the drug withdrawal period.
UR - http://www.scopus.com/inward/record.url?scp=0015091042&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0015091042&partnerID=8YFLogxK
U2 - 10.1002/cpt1971124691
DO - 10.1002/cpt1971124691
M3 - Article
C2 - 4327923
AN - SCOPUS:0015091042
SN - 0009-9236
VL - 12
SP - 691
EP - 697
JO - Clinical pharmacology and therapeutics
JF - Clinical pharmacology and therapeutics
IS - 4
ER -